Skip Navigation Link
Active Repository Program

The Active Repository Program has been established to enable qualified investigators in the U. S. extramural community to investigate materials that, since January 1996, have been judged by the Natural Products Branch to be active in the 60 cell line anti-tumor screen, in addition to those falling into the Open Repository Program. As of February, 1999, over 3,000 samples have been designated as active.

Qualifications for access to the Active Repository

All investigators and organizations requesting access to the Active Repository Program will be required to provide the following information:

  1. A brief description of their assays and their relevance to cancer.
  2. The number of chemists available for bioassay-guided isolation studies.
  3. The types of extracts desired for testing (one or more of marine or terrestrial plants or marine invertebrates).

Distribution of Materials from the Active Repository

Plated Samples: Investigators receiving plated samples through the Open Repository Program may identify extracts restricted to the Active Repository Program. Such extracts may be made available to the investigators providing they qualify for access to the Active Repository, and subject to the 20 sample restriction mentioned above.

On identification of active extracts, investigators will communicate with NPB directly by e-mail of fax, and will be informed whether or not the active materials are available. The test results and requests for additional samples of active extracts are submitted to:

Mrs. Erma Brown
Frederick National Laboratory for Cancer Research (FNLCR)
NPB, DTP, DCTD
P.O. Box B
1050 Boyles Street
Frederick, MD 21701-1201
Phone: 301-624-1285
FAX: 301-631-3026
Email: ebrown@mail.nih.gov

Requests must be copied to:

Dr. Newman newmand@mail.nih.gov

Investigators will have active samples reserved for further investigation on a first-come first-serve basis. Where more than one investigator observes activity for a particular extract, it will be reserved for the first investigator to report activity, and a waiting list of other interested investigators will be established.

Further technical information may be obtained from:

Dr. David Newman
Frederick National Laboratory for Cancer Research (FNLCR)
NPB, DTP, DCTD
P.O. Box B
1050 Boyles Street
Frederick, MD 21701-1201
Phone: 301-624-1285
FAX: 301-631-3026
Email: newmand@mail.nih.gov